Introduction {#sec1}
============

Next generation sequencing technology has revealed that above 90% of the human genome is transcribed to generate an extraordinary range of nonprotein-coding (noncoding) RNAs \[[@B1],[@B2]\]. Long noncoding RNAs (lncRNAs) have no protein-coding function, which are greater than 200 nts in length, influential in remarkable biological processes \[[@B3],[@B4]\]. Compared with miRNAs, lncRNAs are less well understood despite recent interest and attention \[[@B5]\]. Multiple studies have manifested that lncRNAs are involved in wide ranges of physiological and pathophysiological processes, acting in negative or positive feedback loops as oncogenes or tumor suppressor genes \[[@B6]\]. They have been validated as powerful regulatory factors contributing to various cellular processes, including chromatin modifications, gene imprinting, alternative splicing, genome rearrangement, cell proliferation, migration, apoptosis, as well as nuclear--cytoplasmic trafficking \[[@B7]--[@B9]\]. In addition, it reported that lncRNAs could be served as promising biomarkers for diagnosis and potential therapeutic targets in cancers \[[@B10]\]. Therefore, lncRNAs might perform extensive and complex functions in carcinogenesis and human malignancy progression \[[@B11]\]. There are also evidence suggesting that a panel of lncRNAs have been implicated to have abnormal expression patterns in various cancers, and were associated with tumor cell proliferation, apoptosis, metastasis, and invasion \[[@B12]--[@B14]\].

  Terminal differentiation induced ncRNA (TINCR), which was an uncharacterized lncRNA, was demonstrated to be one of the most highly induced lncRNAs of the annotated noncoding RNAs (ncRNAs) during differentiation. The gene of TINCR resides on chromosome 19 in human genome between the *SAFB2* and *ZNRF4* genes \[[@B15]\]. Since that, the prognostic implication of TINCR was rarely studied in hepatocellular carcinoma (HCC). To better understand the functional impact of TINCR, we investigated the TINCR expression level in clinical HCC specimens and adjacent normal control tissues, as well as analyzed its association with disease-free survival (DFS) and overall survival (OS) of patients.

Materials and methods {#sec2}
=====================

Patients and specimens {#sec2-1}
----------------------

The current study has been approved by the Ethics Committee of the Second Affiliated Hospital of Henan University of Chinese Medicine. All patients involved in the present study have provided written informed consents. Briefly, fresh clinical HCC specimens and the adjacent normal tissues were collected from 248 patients who underwent surgery between January 2008 and September 2009 in the Second Affiliated Hospital of Henan University of Chinese Medicine. Tumor TNM stages were identified according to the American Joint Committee on Cancer 2010 TNM classification. All the fresh tissues were put into liquid nitrogen post-operation. The tissues were then stored into a −80°C refrigerator for use. Exclusion criteria: patients receiving any chemotherapy or radiotherapy prior to the surgery or with other cancers. The histopathology of all the tissue specimens were confirmed double-blind by two pathologists in Department of Gastroenterology, Yishui Central Hospital of Linyi City.

Measurement of end points {#sec2-2}
-------------------------

DFS is defined as the time interval elapsed from surgery to the first occurrence of any of the following events: recurrence of HCC, HCC distant metastasis, or death from any cause without documentation of a cancer-related event. OS is defined as the time interval elapsed from surgery to death in patients with HCC. Death of participants was ascertained by reporting from the family and verified by review of public record. DFS and OS status was recorded by clinical staff blinded to participant status, including clinicopathologic or TINCR expression data.

Cell culture {#sec2-3}
------------

HUH7 (human HCC cell line) were purchased from the American Type Culture Collection (Manassas, VA, U.S.A.). The cells were maintained in RPMI-1640 medium (Cat\# 11354-035, Invitrogen-Gibco) containing 10% heat-inactivated FBS (Cat\# 0354-4213, Invitrogen-Gibco), 2 mM [L]{.smallcaps}-glutamine, and 100 U/ml penicillin/streptomycin at 37°C in a humidified atmosphere containing 5% CO~2~. For cell transfection, exponentially growing cells (1.5 × 10^5^) were seeded in 12-well plates and transfected with 30 nM miRNA mimics or the negative control (GenePharma, Shanghai, China) using Lipofectamine 3000 (Life Technologies, Carlsbad, CA, U.S.A.) according to the manufacturer's instructions.

Quantitative real-time RT-PCR (qRT-PCR) {#sec2-4}
---------------------------------------

Total RNA was extracted from clinical specimens using the TRIzol reagent (Cat\# 15596-026, Gibco BRL and Life Technologies) following manufacturer's instructions. The total RNA was reverse transcribed to cDNA using a cDNA Reverse Transcription Kit (Cat\# 35412-011, Promega Inc., U.S.A.). cDNA sample was analyzed in triplicate on an ABI 7500 system (Applied Biosystems) using SYBR Green according to the manufacturer's instructions. ACTIN was used as an internal control. Primers used were as follows: TINCR, forward: 5′-CCATCCCTCTGTAACCACCT-3′ and reverse: 5′-GTTGGGTCTAGATTCCAGCA-3′; ACTIN, forward: 5′-ATCATGTTTGCCTAGATCAACA-3′ and reverse: 5′-CATCTCTTGCTAAGCGTCCA-3′. The PCR conditions were as follows: 95°C for 10 min for initial denaturation followed by 45 cycles of 95°C for 10 s, 60°C for 35 s, 72°C for 30 s, and then a final extension of 10 min. The relative mRNA levels were quantitated and analyzed using the SDS system software (Applied Biosystems) The relative quantitation of *TINCR* mRNA was performed using the 2^−ΔΔ*C*^~t~ method. The experiments were repeated at least thrice.

Western blotting {#sec2-5}
----------------

Cells were washed and lysed in lysis buffer (10 mM KCl, 20 mM HEPES, 5 mM EDTA, 1% NP-40, 0.25% deoxycholate, pH 7.4) containing protease and phosphatase inhibitors. After incubation on ice for 20 min, the lysate was centrifuged at 12000 r.p.m. for 20 min at 4°C, and the supernatant was collected. The protein concentration was assessed using a standard BCA assay (Beyotime). For each sample, 60 μg of protein was separated on SDS-PAGE (10% gel) (Bio--Rad), transferred on to a PVDF membrane (Cat\#: 3010040001; Roche Applied Science, Mannheim, Germany). After blocking with 5% milk in TBST (0.1% TBS-Tween 20) at room temperature for 1.5 h, the membrane was washed three times with TBST and incubated with monoclonal mouse anti-TINCR polyclonal antibody (1:2000, Abcam, Cambridge, MA, U.S.A.) or monoclonal rabbit anti-β-actin antibody (1:2000, Abcam, Cambridge, MA, U.S.A.) overnight at 4°C. After washing with PBS for 10 min, the membrane was incubated with mouse anti-rabbit secondary antibody (1:20000, Abcam, Cambridge, MA, U.S.A.) for 1 h at room temperature. After washing with PBS for 15 min, protein bands were detected using the ECL Western Blotting Kit (Pierce Chemical, Rockford, IL, U.S.A.). The relative protein expression was analyzed by Image-Pro Plus software 6.0, represented as the density ratio compared with β-actin.

Luciferase reporter assay {#sec2-6}
-------------------------

The *TINCR* mRNA 3′-UTR fragment was amplified by PCR and inserted into the pmirGLO miRNA target expression vector (Promega, San Luis Obispo, CA, U.S.A.) to construct pmirGLO-TINCR (3′-UTR) plasmid. For the luciferase reporter assay, cells were cotransfected with miRNA mimics (50 nM) or negative control (50 nM), and pmirGLO-TINCR (3′-UTR) (50 nM) with Lipofectamine 3000 (Life Technologies, Carlsbad, CA, U.S.A.), according to the manufacturer's instructions. After transfection for 48 h, the activities of *Renilla* luciferase and firefly luciferase were determined by the dual-luciferase reporter assay system (Promega). The luciferase activity was normalized to the firefly luciferase activity.

Statistical analysis {#sec2-7}
--------------------

Statistical analysis was performed using the R Statistical Software Package (version 3.1.3). Statistical comparisons were performed using Student's *t* test. The correlations between TINCR expression level and the clinical parameters were analyzed by Pearson's χ^2^ test or Fisher's exact test. DFS and OS survival curves were analyzed by the Kaplan--Meier method, and the difference was calculated by the log rank test. The independence of TINCR in prognosis was estimated using the multivariate Cox proportional hazards regression model. Differences were considered significant for *P*\<0.05.

Results {#sec3}
=======

TINCR expression in HCC patients {#sec3-1}
--------------------------------

The expression levels of TINCR in 248 HCC samples and matched para-carcinoma specimens were detected by quantitative real-time RT PCR (qRT-PCR). Results showed that *TINCR* mRNA expression level was significantly up-regulated in HCC samples compared with the corresponding control samples (P\<0.01, [Figure 1](#F1){ref-type="fig"}), suggesting that aberrant TINCR expression might be correlated with HCC pathogenesis. Then, we assigned HCC samples to TINCR low-expression group and TINCR high-expression group that were tumors with TINCR expression under and above the median value of expression in all 248 gliomas, respectively (*n*=138 and 110 for low-expression group and high-expression group, respectively).

![Expression of TINCR detected by real-time PCR\
Relative expression of TINCR in HCC specimens and adjacent normal control liver tissues (*n*=248).](bsr-37-bsr20170301-g1){#F1}

Association of TINCR expression with clinicopathological parameters of HCC patients {#sec3-2}
-----------------------------------------------------------------------------------

After tumor tissues were classified into two subgroups (high-TINCR expression subgroup and low-TINCR expression subgroup), the association of TINCR expression level with clinicopathological characteristics of HCC patients were further analyzed. Results showed that the TINCR expression level was associated with tumor size (*P*=0.005), differentiation (*P*=0.017), vascular invasion (*P*=0.004), and TNM stage (*P*=0.010), which indicated that high TINCR expression was probably to present larger tumor size, advanced clinical stage, enhanced invasion degree, and less tumor differentiation. However, no correlation was found between TINCR expression and gender, age at diagnosis, alanine transaminase (ALT), α-fetoprotein (AFP), hepatitis B surface antigen (HbsAg), or hepatitis history (*P*\>0.05, [Table 1](#T1){ref-type="table"}).

###### Association of TINCR expression with clinicopathologic parameters

  Clinicopathologic parameters   *n*   TINCR expression   *P*-value   
  ------------------------------ ----- ------------------ ----------- -------
  Total                          248   138                110         
  **Age**                                                             0.194
  \<55 years                     133   74                 59          
  ≥55 years                      115   64                 51          
  **Gender**                                                          0.764
  Male                           184   103                81          
  Female                         64    35                 29          
  **ALT (U/l)**                                                       0.851
  ≤75                            211   116                95          
  \>75                           37    22                 15          
  **AFP (ng/ml)**                                                     0.307
  \>20                           157   81                 76          
  ≤20                            91    57                 34          
  **Hepatitis history**                                               0.772
  Present                        179   101                78          
  Absent                         69    37                 32          
  **Vascular invasion**                                               0.004
  Present                        69    29                 40          
  Absent                         179   109                70          
  **Liver cirrhosis**                                                 0.861
  Present                        122   61                 61          
  Absent                         126   77                 49          
  **Tumor size (cm)**                                                 0.005
  ≤5                             124   77                 47          
  \>5                            124   61                 63          
  **Differentiation status**                                          0.017
  Well/Moderate                  165   100                65          
  Poor-undifferentiated          83    38                 45          
  **TNM stage**                                                       0.010
  I + II                         159   97                 62          
  III + IV                       89    41                 48          
  **HbsAg**                                                           0.881
  Present                        44    23                 21          
  Absent                         204   115                89          

Association of TINCR expression with DFS of patients {#sec3-3}
----------------------------------------------------

The association of DFS and TINCR expression of HCC patients was evaluated by Kaplan--Meier analysis ([Table 2](#T2){ref-type="table"}). Results showed that patients with high TINCR expression in HCC tissues had unfavorable DFS compared to those with low TINCR expression ([Figure 2](#F2){ref-type="fig"}, log-rank test: P=0.017). At the 5-year follow-up, disease-free patients with low TINCR expression accounted for 47.5%, whereas disease-free patients with high TINCR expression accounted for 22.3%. This result indicated that HCC patients with high TINCR expression had a relatively higher risk of tumor relapse compared to those with low TINCR expression. Also, tumor size (log-rank test: *P*=0.001), AFP (log-rank test: *P*=0.002), differentiation status (log-rank test: *P*=0.036) and TNM stage (log-rank test: *P*=0.004), and vascular invasion (log-rank test: *P*=0.000) were also shown to be associated with DFS. However, no significant correlation was found amongst gender, age at diagnosis, or liver cirrhosis and DFS of patients with HCC. Moreover, multivariate analysis showed that TINCR as an independent prognostic factor for DFS ([Table 3](#T3){ref-type="table"}, HR =1.32, 95% CI: 1.00--1.57, *P*=0.000).

![Kaplan--Meier curves for DFS of HCC patients with high and low *TINCR* mRNA expression levels\
Patients with high *TINCR* mRNA levels (fold change ≥2) tended to have a shorter DFS time (*P*=0.000).](bsr-37-bsr20170301-g2){#F2}

###### Association of TINCR and clinical factors with DFS

  Clinicopathologic parameters                       Hazard ratio   95% Confidence interval   *P*-value   
  -------------------------------------------------- -------------- ------------------------- ----------- -------
  Age (years) (\<55 compared with ≥55)               0.81           0.52                      1.29        0.321
  Gender (male compared with female)                 1.05           0.64                      1.76        0.933
  AFP (ng/ml) (\<20 compared with ≥20)               1.98           1.77                      2.34        0.002
  HbsAg (absent compared with present)               1.03           0.56                      1.82        0.931
  Liver cirrhosis (absent compared with present)     1.15           0.75                      1.79        0.568
  Tumor size (cm) (\<5 compared with ≥5)             1.93           1.64                      2.36        0.001
  TNM stage (I--II compared with III--IV)            2.26           1.27                      3.88        0.004
  Differentiation status (well/moderate)             2.27           1.24                      4.65        0.036
  Vascular invasion (absent compared with present)   1.93           1.59                      2.28        0.000
  TINCR expression (low compared with high)          1.82           1.28                      2.55        0.001

###### Multivariate analyses of clinicopathological and TINCR expression for DFS

  Clinicopathologic parameters                       Hazard Ratio   95% Confidence interval   *P*-value   
  -------------------------------------------------- -------------- ------------------------- ----------- -------
  Tumor size (cm) (\<5 compared with ≥5)             1.38           1.04                      1.71        0.010
  AFP (ng/ml) (\<20 compared with ≥20)               1.47           1.14                      1.86        0.004
  Vascular invasion (absent compared with present)   1.35           1.01                      1.64        0.008
  TINCR expression (low compared with high)          1.32           1.00                      1.57        0.000

Association of TINCR expression with OS of patients {#sec3-4}
---------------------------------------------------

As shown in [Table 4](#T4){ref-type="table"}, there was a statistically significant association between OS and TINCR expression level (*P*\<0.01). Kaplan--Meier analysis showed that patients with HCC of high TINCR expression had worse OS compared with patients with tumor of low TINCR expression ([Figure 3](#F3){ref-type="fig"}, log-rank test: *P*=0.004). At the 5-year follow-up, survived patients with low TINCR expression accounted for 77.8%, whereas survived patients with high TINCR expression accounted for 61.4%. In addition, differentiation status (log-rank test: *P*=0.005), AFP (log-rank test: *P*=0.010), tumor size (log-rank test: *P*=0.001), and TNM stage (log-rank test: *P*=0.000) were all identified to be prognostic factors for OS of patients with HCC. However, no prognostic value of gender, age, HbsAg, or liver cirrhosis was found on OS of HCC patients. Moreover, multivariate analysis showed TINCR as an independent prognostic factor for OS ([Table 5](#T5){ref-type="table"}, HR =1.57, 95% CI: 1.30--1.86, *P*=0.004).

![Kaplan--Meier curves for OS of HCC patients with high and low *TINCR* mRNA expression levels\
Patients with high *TINCR* mRNA levels (fold change \<2) tended to have a shorter OS time (*P*=0.004).](bsr-37-bsr20170301-g3){#F3}

###### Association of TINCR and clinical factors with OS

  Clinicopathologic parameters                       Hazard ratio   95% Confidence interval   *P*-value   
  -------------------------------------------------- -------------- ------------------------- ----------- -------
  Age (years) (\<55 compared with ≥55)               0.77           0.37                      1.55        0.446
  Gender (male compared with female)                 1.00           0.45                      2.23        1.000
  AFP (ng/ml) (\<20 compared with ≥20)               1.68           1.33                      2.04        0.010
  HbsAg (absent compared with present)               1.52           0.56                      3.92        0.471
  Liver cirrhosis (absent compared with present)     1.49           0.77                      2.95        0.224
  Tumor size (cm) (\<5 compared with ≥5)             1.57           1.18                      1.90        0.001
  TNM stage (I--II compared with III--IV)            22.1           5.62                      87.6        0.000
  Differentiation status (well/moderate)             2.15           1.29                      3.85        0.005
  Vascular invasion (absent compared with present)   1.54           1.23                      1.96        0.002
  TINCR expression (low compared with high)          1.63           1.23                      2.54        0.002

###### Multivariate analyses of clinicopathological and TINCR expression for OS

  Clinicopathologic parameters                       Hazard ratio   95% Confidence interval   *P*-value   
  -------------------------------------------------- -------------- ------------------------- ----------- -------
  Tumor size (cm) (\<5 compared with ≥5)             1.62           1.34                      1.97        0.001
  AFP (ng/ml) (\<20 compared with ≥20)               1.71           1.47                      2.09        0.000
  TNM stage (I--II compared with III--IV)            1.18           0.92                      1.49        0.224
  Differentiation status (well/moderate)             1.17           0.96                      1.33        0.236
  Vascular invasion (absent compared with present)   1.46           1.14                      1.77        0.000
  TINCR expression (low compared with high)          1.57           1.30                      1.86        0.004

TINCR expression was inhibited by *miR-137* and *miR-133a* {#sec3-5}
----------------------------------------------------------

In order to investigate whether TINCR expression could be regulated by miRNAs in HCC, prediction algorithms, including miRWalk \[[@B16]\] and starBase \[[@B17]\] were used to screen the miRNAs that potentially target TINCR. Based on these data and the previous reports about the candidate miRNAs' function, six cancer-related or tumor-suppressing miRNAs were chosen for further investigation, including *miR-198, miR-126, miR-133a, miR-137, miR-22*, and *miR-372* \[[@B18]--[@B23]\]. The luciferase assays demonstrated that *miR-137* and *miR-133a*, rather than *miR-126, miR-22*, and *miR-372* could significantly suppress the luciferase activity in pmirGLO-TINCR (3′-UTR) and miRNAs cotransfected cells ([Figure 4](#F4){ref-type="fig"}). Data showed that *miR-137* and *miR-133a* transfection led to 45.14 ± 7.31% and 35.87 ± 3.24% decrease in luciferase activity in HUH7 cells, respectively ([Figure 4](#F4){ref-type="fig"}A, *P*=0.002 and 0.006). We next detected whether *miR-137* and *miR-133a* could decrease *TINCR* mRNA expression levels in HCC cells. Results showed that *miR-137* and *miR-133a* could significantly reduce the *TINCR* mRNA expression level by 56.74 ± 4.92% and 50.13 ± 8.64% in HUH7 cells ([Figure 4](#F4){ref-type="fig"}B, *P*=0.003 and 0.002), respectively. Moreover, the expression of TINCR protein was inhibited significantly in HUH7 cells by *miR-137* and *miR-133a*, with the TINCR protein level decreased to 58.96 ± 2.52% and 35.03 ± 8.85% ([Figure 4](#F4){ref-type="fig"}C,D, *P*=0.001 and 0.017), respectively. These data suggest that TINCR is a direct target of *miR-137*/*miR-133a*, which is suppressed by *miR-137*/*miR-133a*.

![TINCR expression was inhibited by *miR-137*/*miR-133a*\
(**A**) *miR-137, miR-133a*, and *miR-137*/*miR-133a* cotransfection could suppress the luciferase activity in pmirGLO-TINCR transfected HUH7 cells. (**B**) Compared with negative control, *miR-137, miR-133a*, and *miR-137*/*miR-133a* cotransfection could significantly reduce the *TINCR* mRNA expression in HUH7 cells. (**C, D**) *miR-137, miR-133a*, and *miR-137*/*miR-133a* cotransfection led to dramatic reduction in TINCR protein expression in HUH7 cells. \**P*\<0.05.](bsr-37-bsr20170301-g4){#F4}

To investigate whether *miR-137* and *miR-133a* could synergistically inhibit TINCR expression in HCC, the HUH7 cells were cotransfected with *miR-137* and *miR-133a*, and subjected to luciferase assay and TINCR expression detection. We found that *miR-137* and *miR-133a* co-transfection significantly decreased the luciferase activity (40.59 ± 6.37%), *TINCR* mRNA expression (53.06 ± 10.84%) and TINCR protein level (47.55± 5.08%) in HUH7 cells ([Figure 4](#F4){ref-type="fig"}, *P*\<0.05). However, *miR-137*/*miR-133a* cotransfection showed no significant changes when compared with *miR-137* or *miR-133a* alone ([Figure 4](#F4){ref-type="fig"}, *P*\> 0.05). Although *miR-137*/*miR-133a* cotransfection seemed to show more power than *miR-133a* in suppressing the expression of TINCR, it displayed less activity than *miR-137*. Therefore, we could not conclude that *miR-137* and *miR-133a* have synergistic roles in inhibiting TINCR expression in HCC.

Discussion {#sec4}
==========

HCC accounts for approximately 70--90% of primary liver carcinoma worldwide, becoming one of the top three major causes of cancer-related mortality \[[@B24]\]. Recently, novel strategies, such as gene therapy and targetted therapy have become available and have been developed for HCC treatment. However, the 5-year survival rate for patients with HCC is still very low \[[@B14]\]. Therefore, to develop novel and reliable biomarkers, it is necessary for evaluation of the prognosis and efficacy of the therapeutic strategies for HCC.

Recently, several literatures indicated that expressions of lncRNAs were significantly altered between HCC tissues and nontumor tissues by lncRNAs microarray technology interrogating putative lncRNAs. For example, Zhu et al. \[[@B25]\] suggested 174 lncRNAs were differentially expressed between five pairs of HCC samples and nontumor samples. Gao et al. \[[@B26]\] conducted the study that aberrant expression of lncRNAs might be responsible for the HCC invasion and metastasis. Zhang et al. \[[@B27]\] reported that LINC01419 was significantly up-regulated in HBV-related and HCV-related HCC when compared with matched nontumor liver tissues.

However, the prognostic implication of TINCR was rarely studied. Current reports showed that TINCR had remarkable impacts on cell proliferation, apoptosis, and angiogenesis promotion, therefore regarding as a biomarker which was significantly associated with cancer metastasis and unfavorable prognosis \[[@B28],[@B29]\]. TINCR expression was significantly up-regulated in bladder cancer tissues and cells, showing strongly increased TINCR expression level in the higher tumor stage \[[@B30]\]. In human gastric carcinoma, up-regulated TINCR was found to contribute to oncogenesis and cancer progression through influencing cell proliferation and apoptosis \[[@B31]\]. In addition, aberrant TINCR expression has also been demonstrated in human squamous cell carcinoma \[[@B32],[@B33]\]. In the current study, HCC patients with high TINCR expression had larger tumor size and advanced stage, suggesting that TINCR could be involved in the development and progression of HCC. Furthermore, RT-PCR results revealed that TINCR was significantly up-regulated in HCC. Up-regulation of TINCR expression has been demonstrated to remarkably correlate with tumor size, tumor differentiation, TNM stage and vascular invasion, which revealed that TINCR expression was correlated with advanced tumor progression and aggressive clinicopathological features. High TINCR expression served as an independent factor in unfavorable survival and worse outcomes in HCC patients. Our data suggest that TINCR expression could be a valuable marker of prognosis and malignant progression of glioma.

In the present study, lncRNA TINCR was identified as an independent factor for DFS and OS in a cohort of 248 patients with HCC. Patients with high TINCR expression had a shorter survial rate than those with low TINCR expression. These data demonstrated that TINCR was of clinical implication in prognosis of patient with HCC. As far as we know, this is the first study that proposes the clinical significance of TINCR expression in predicting the OS and RFS of patients with HCC. In our study, up-regulation of TINCR expression was closely associated with HCC progression. These findings may provide a new potential therapeutic biomarker for HCC diagnosis. However, further investigations are needed to illuminate the detailed molecular mechanism by which lncRNA TINCR plays a role in HCC.
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